---
title: "Inventiva S.A. (IVA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/IVA.US.md"
symbol: "IVA.US"
name: "Inventiva S.A."
industry: "Biotechnology"
datetime: "2026-05-21T12:20:45.663Z"
locales:
  - [en](https://longbridge.com/en/quote/IVA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/IVA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/IVA.US.md)
---

# Inventiva S.A. (IVA.US)

## Company Overview

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [inventivapharma.com](https://inventivapharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:19.000Z

**Overall: D (0.72)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 223 / 385 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -48.63% |  |
| Net Profit YoY | -105.86% |  |
| P/B Ratio | -29.45 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 986498113.42 |  |
| Revenue | 7790129.42 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 523.99% | A |
| Profit Margin | -5237.95% | E |
| Gross Margin | 99.67% | A |
| Revenue YoY | -48.63% | E |
| Net Profit YoY | -105.86% | E |
| Total Assets YoY | 136.83% | A |
| Net Assets YoY | 69.80% | A |
| Cash Flow Margin | 29.62% | D |
| OCF YoY | -48.63% | E |
| Turnover | 0.04 | E |
| Gearing Ratio | 111.43% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Inventiva S.A.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-48.63%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-105.86%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-29.45",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "986498113.42",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "7790129.42",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "523.99%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-5237.95%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "99.67%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-48.63%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-105.86%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "136.83%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "69.80%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "29.62%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-48.63%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.04",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "111.43%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.42 | 267/385 | - | - | - |
| PB | -29.45 | 537/385 | - | - | - |
| PS (TTM) | 126.63 | 262/385 | 66.75 | 46.33 | 30.95 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-13T04:00:00.000Z

Total Analysts: **13**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 11 | 85% |
| Overweight | 2 | 15% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 5.14 |
| Highest Target | 26.00 |
| Lowest Target | 8.80 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/IVA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/IVA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/IVA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/IVA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**